Lung Cancer Dispatch
4.6K views | +1 today
Follow
Lung Cancer Dispatch
News for Patients and Physicians
Curated by Cancer Commons
Your new post is loading...
Your new post is loading...
Suggested by Cancer Commons
Scoop.it!

Phase II Study Shows New Drug is Effective against NSCLC

Phase II Study Shows New Drug is Effective against NSCLC | Lung Cancer Dispatch | Scoop.it

Preliminary results from an ongoing phase II clinical trial of new lung cancer drug AXL1717 suggest that the drug is effective against non-small cell lung cancer (NSCLC). Patients with advanced NSCLC received either AXL1717 or chemotherapy with docetaxel (Taxotere) as a second-line treatment. AXL1717, which acts by inhibiting a protein called IGF1R, appeared to be as effective as Taxotere at delaying cancer progression. AXL1717 may be a treatment option for patients who do not respond or become resistant to Taxotere or other second-line treatments. AXL1717 is manufactured by drug company Axelar. More information about the clinical trial can be found here: http://clinicaltrials.gov/show/NCT01561456

Cancer Commons's insight:

News-Medical.Net | Apr 2, 2013

more...
No comment yet.
Scooped by Cancer Commons
Scoop.it!

Overexpression of IGF1R and EGFR Genes May Worsen Lung Cancer Prognosis

The roles of the genes IGF1R and EGFR in lung cancer were examined in patients with non-small cell lung cancer (NSCLC) who had their primary tumor surgically removed. Patients whose tumors had increased expression of both IGFR1R and EGFR were more likely to experience recurrence of the cancer after a shorter amount of time and had shorter survival times after surgery. This finding suggests that concurrent overexpression of IGF1R and EGFR is a negative prognosis factor in NSCLC and may indicate patients who are more likely to benefit from novel treatments with IGF1R inhibitors.


Research paper: http://link.springer.com/article/10.1007/s00280-012-2056-y/fulltext.html

Cancer Commons's insight:

Cancer Chemotherapy and Pharmacology | Jan 12, 2013

more...
No comment yet.